FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | ||
|
|||
Magnate
|
|
||
![]() |
![]() |
![]() |
#2 | ||
|
|||
Member
|
Quote:
Interesting that there was almost no mention, other than the failed study, of CERE-120. All Sangamo was touting was CERE-110 (for AD). I guess we shouldn't be looking for any new CERE-120 trials anytime soon, if ever again. |
||
![]() |
![]() |
![]() |
#3 | ||
|
|||
Magnate
|
i'm not qualified to comment on the bigger picture but they sure got em for peanuts. better than going bk like neurologix.
will be interesting to see if mjff and/or other researchers comment. |
||
![]() |
![]() |
Reply |
|
|
![]() |
||||
Thread | Forum | |||
ZFP Therapy Sangamo BioSciences Announces Publication of Data From Prog to Develop | Parkinson's Disease | |||
ZFP Therapy Sangamo BioSciences Announces Publication of Data From Prog to Develop | Parkinson's Disease Clinical Trials | |||
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lat | ALS News & Research |